Abstract explained Jan101's statistically
significant reduction in pain and improvement in nerve conduction
velocity in prior Phase II study.
LAS
VEGAS, Aug. 25, 2023 /PRNewswire/ -- JanOne
(Nasdaq: JAN), the biopharmaceutical company focused on developing
non-addicting painkillers and novel treatments for the causes of
pain, has won a prestigious "Best Abstract" award for reporting
that JanOne's treatment for diabetic neuropathy showed both
effectiveness against pain and potential to improve nerve
function.
The abstract was presented at the annual meeting of the Ohio
Society of Interventional Pain Physicians (OHSIPP), one of the
nation's largest regional pain management meetings typically
attracting 300 physicians from around the country. The JanOne
abstract, selected as one of the top three, analyzed prior data on
Jan101's randomized double blind placebo-controlled trial in
diabetic neuropathy patients.
Dr. Amol Soin, JanOne's Chief Medical Officer, submitted
the phase II trial abstract, which was first accepted for
presentation after peer review and then honored as one of the top
three best.
"Winning this award is a gratifying validation by independent
peers of the work we are doing," Dr. Soin said. "Our data
showed that Jan101 may not only provide a non-opioid treatment for
diabetic neuropathy pain, but also showed statistically significant
improvement in nerve conduction velocity. This finding
indicates that Jan101 may actually improve nerve function."
"We were honored to be recognized by peer physicians who see the
value of our research and our work," said Tony Isaac, JanOne's
Chief Executive Officer. "We look forward to continuing to advance
our drug portfolio to help people who suffer with debilitating pain
by finding non-opioid based treatments."
About JanOne Inc.
JanOne is a unique
Nasdaq-listed company offering innovative, actionable solutions
intended to help end the opioid crisis. JanOne is dedicated to
funding resources toward innovation, technology, and education to
find a key resolution to the national opioid epidemic, which is one
of the deadliest and most widespread in the nation's history. Its
drugs in the clinical trial pipeline have shown promise for their
innovative targeting of the causes of pain as a strategic option
for physicians averse to exposing patients to addictive opioids.
Please visit www.janone.com for additional
information.
Forward Looking Statements
This press release contains statements that are forward-looking
statements as defined within the Private Securities Litigation
Reform Act of 1995, including, but not limited to, statements
relating to the statements that JAN 101 will treat PAD, that JAN
123 will treat CRPS, the timing of the commencement of clinical
trials, that the FDA will permit approval through a 505(b)(2)
pathway for JAN 123, that upon approval JAN 101 will immediately
disrupt the PAD market, and other statements, including words such
as "continue", "expect", "intend", "will", "hope" "should",
"would", "may", "potential" and other similar expressions. Such
statements reflect JanOne's current view with respect to future
events, are subject to risks and uncertainties, and are necessarily
based upon a number of estimates and assumptions that, while
considered reasonable by JanOne, are inherently subject to
significant business, economic, competitive, political and social
uncertainties and contingencies. Many factors could cause JanOne's
actual results, performance or achievements to be materially
different from any future results, performance or achievements
described in this press release. Such factors could include,
among others, those detailed in the Company's periodic reports
filed with the Securities and Exchange Commission (the "SEC").
Should one or more of these risks or uncertainties materialize, or
should the assumptions set out in the section entitled "Risk
Factors" in JanOne's filings with the SEC underlying those
forward-looking statements prove incorrect, actual results may vary
materially from those described herein. These forward-looking
statements are made as of the date of this press release and JanOne
does not intend, and does not assume any obligation, to update
these forward-looking statements, except as required by law. JanOne
cannot assure that such statements will prove to be accurate as
actual results and future events could differ materially from those
anticipated in such statements. Individuals are cautioned that
forward-looking statements are not guarantees of future performance
and accordingly investors are cautioned not to put undue reliance
on forward-looking statements due to the inherent uncertainty
therein.
Media Contact
Investor Relations
IR@janone.com
1-800-400-2247
View original content to download
multimedia:https://www.prnewswire.com/news-releases/janone-wins-best-abstract-award-at-the-ohio-society-of-interventional-pain-physicians-annual-meeting-301910293.html
SOURCE JanOne Inc.